TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06228404
Drug: Enhanced autologous PSMA-CAR T
Normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 escalated dosing cohorts are designed to explore safety and efficacy of enhanced autologous PSMA-CAR T:~cohort A： CART-PSMA cells 0.25×106/kgBW, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol;~cohort B： CART-PSMA cells 0.75×106/kgBW，following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol;~cohort C： CART-PSMA cells 2×106/kgBW，following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol;
Study: NCT05205993
Drug: Intrauterine infusion
Normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total of 10 intrauterine infusions of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
Study: NCT05205993
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day and metronidazole of 500mg twice a day for a total of 30 days
Study: NCT05518513
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: adductor canal block with 0.25% bupivacaine
Study: NCT06006689
Drug: Low dose Qishen Yiqi Dripping Pills 3 bags
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 2 bags(0.52g dripping pills per bag) and Qishen Yiqi dripping pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
Study: NCT06006689
Drug: High dose Qishen Yiqi Dripping Pills 3 bags
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks
Study: NCT05971667
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tadalafil 10 mg one tablet daily
Study: NCT05971667
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sildenafil 20 mg two tablets daily
Study: NCT05971667
Drug: pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pentoxifylline 400 mg two tabs daily
Study: NCT05764928
Drug: BLEX 404
Normalized name: Bleximenib
DrugBank: Bleximenib (DB19328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLEX 404 Oral Liquid, PO, BID
Study: NCT06413615
Drug: FDA022-BB05
Normalized name: OCTINOXATE 50 mg in 1 mL TOPICAL CREAM [Flormar BB BB05 Medium]
DrugBank: Octinoxate (DB09496)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monoclonal antibody-drug conjugate for injection
Study: NCT06327932
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (3g/150ml NS).
Study: NCT05841160
Drug: Ecopipam Hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Ecopipam (DB12273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets
Study: NCT05841160
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet
Study: NCT05992155
Drug: TAK-279
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-279 capsules.
Study: NCT06234137
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
Study: NCT06234137
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC=6 min/mL iv 3-weekly
Study: NCT06234137
Drug: Inetetamab
Normalized name: Inetetamab
DrugBank: Inetetamab (DB17457)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
Study: NCT06234137
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg orally daily
Study: NCT04690283
Drug: Danggui-Sini granules
Normalized name: Ephedra sinica root
DrugBank: Ephedra sinica root (DB01363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention relates to a traditional Chinese prescription granules, which contains angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root.
Study: NCT04802447
Drug: SurVaxM
Normalized name: SurVaxM
DrugBank: SurVaxM (DB17397)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will receive 4 doses of SVN53-67/M57-KLH (SurVaxM) spaced two weeks apart. This phase of treatment is known as the prime-boost phase and will take 6 weeks to complete. After completion of the prime-boost phase of treatment, the participant will receive a dose ofSVN53-67/M57-KLH (SurVaxM) every 3 months for up to two years
Study: NCT06268860
Drug: Rocatinlimab vial injection
Normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vial solution for SC injection administered on Day 1
Study: NCT05159908
Drug: NBI-921352
Normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration
Study: NCT04900311
Drug: pyrotinib + trastuzumab + nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patients will be treated every 3 weeks for four cycles prior to surgery at following doses: pyrotinib: 400 mg/day, orally, qd trastuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 8 mg/kg in Cycle 1, and 6 mg/kg in Cycles 2-4 nab-paclitaxel: 260 mg/m2 IV infusion on Day 1 every 3 weeks, or 125 mg/m2 IV infusion on Days 1, 8 and 15 every 3 weeks (the nab-paclitaxel administration cycle was determined by investigator at each site)
Study: NCT04900311
Drug: pertuzumab + trastuzumab + nab-paclitaxel
Normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patients will be treated every 3 weeks for four cycles prior to surgery at following doses: pertuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 840 mg for Cycle 1, followed by 420 mg for Cycles 2-4 trastuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 8 mg/kg in Cycle 1, and 6 mg/kg in Cycles 2-4 nab-paclitaxel: 260 mg/m2 IV infusion on Day 1 every 3 weeks, or 125 mg/m2 IV infusion on Days 1, 8 and 15 every 3 weeks (the nab-paclitaxel administration cycle was determined by investigator at each site)
Study: NCT05697640
Drug: Vericiguat Oral Tablet
Normalized name: vericiguat Oral Tablet
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The treatment period includes ten weeks of daily vericiguat or placebo intake (depending on randomization) and a 30-day follow-up period (no vericiguat/placebo intake).
Study: NCT06297096
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 162 mg s.c./week
Study: NCT06297096
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib - established doses of nintedanib for adults in the treatment of ILD, also SSc-ILD: 2 x 150 mg daily, in the event of e.g. increased liver enzyme levels, poorer treatment tolerance (e.g. diarrhea), the dose can be reduced to 2 x 100 mg
Study: NCT05064280
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV (200 mg IV D1 Q3W)
Study: NCT05064280
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by PO (20 mg PO QD)
Study: NCT00540605
Drug: Tenofovir 1% vaginal gel
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topical gel containing 1% tenofovir
Study: NCT04810754
Drug: Daratumumab Injection
Normalized name: daratumumab Injection
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1800 mg per injection; 8 consecutive injections once a week; subcutaneous application in abdomen
Study: NCT05167071
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be treated with Toripalimab on Day 1 during each 21-day cycle.
Study: NCT06222801
Drug: Interferon gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunostimulating agent.
Study: NCT05527470
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent chemotherapy: Patients received 100mg/m2 cisplatin intravenously on day 1 to 3, three cycles were administered at intervals of 3 weeks.
Study: NCT00000816
Drug: Sulfamethoxazole-Trimethoprim
Normalized name: sulfamethoxazole-trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05943223
Drug: Piperacillin/tazobactam
Normalized name: PIPERACILLIN/TAZOBACTAM
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-operative piperacillin/tazobactam 100 mg/kg IV q8h (to a maximum of 4.5 g IV q8h)
Study: NCT06340789
Drug: Sodium Benzoate 2gram/day
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the add-on sodium benzoate with conventional pharmacological treatment
Study: NCT05943223
Drug: CefTRIAXone Injection
Normalized name: ceftriaxone Injection
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-operative ceftriaxone 50 mg/kg IV once daily (to a maximum of 2 g IV once daily)
Study: NCT05943223
Drug: Metronidazole Injection
Normalized name: metronidazole Injection
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-operative metronidazole 10 mg/kg IV q8h (to a maximum of 500 mg IV q8h)
Study: NCT00944177
Drug: Metformin HCl
Normalized name: metformin HCl
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05276609
Drug: HS-20093 (Phase Ia: Dose escalation)
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Study: NCT05276609
Drug: HS-20093 (Phase Ib: Dose expansion)
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Study: NCT05791721
Drug: Dexamethasone 4mg
Normalized name: DEXAMETHASONE 4MG TAB
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intervention will be applied one hour before surgical extraction of impacted mandibular third molar
Study: NCT05508516
Drug: Duloxetine Hydrochloride
Normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will accept duloxetine hydrochloride 20mg (twice, per day) for 12 weeks.
Study: NCT05095519
Drug: 18F-DCFPyL
Normalized name: 18F-DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-DCFPyL will be administered with a single dose of 3.5 MBq per kg (2-4 MBq per kg), maximum 400 MBq), administered as a slow (over 30 seconds) intravenous injection
Study: NCT04740008
Drug: Low Nicotine Content Cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low Nicotine Content Cigarettes 0.4 mg/g nicotine; 9 mg tar Other Name: Reduced Nicotine Content Cigarettes
Study: NCT05948085
Drug: Zavegepant 10 mg IN
Normalized name: zavegepant 10 MG
DrugBank: Zavegepant (DB15688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive zavegepant 10 mg IN spray in period 1 and a butterscotch candy + zavegepant 10 mg IN spray in period 2
Study: NCT04611880
Drug: Crizanlizumab
Normalized name: Crizanlizumab
DrugBank: Crizanlizumab (DB15271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: crizanlizumab is a humanized monoclonal anti-P-selectin antibody that prevents leukocyte adhesion to the vascular endothelium, thereby limiting risk of microvascular occlusion. It is administered intravenously.
Study: NCT00001091
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00001091
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001091
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001091
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00001091
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04795141
Drug: ABY-035
Normalized name: Affibody aby-035 (recombinant human interleukin 17a-binding)
DrugBank: Izokibep (DB19081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABY-035 Solution for injection
Study: NCT05688332
Drug: Voglibose + Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In treatment group B, 59 participants will also be randomly assigned to the voglibose 0.2/0.3mg TDS + metformin 500mg BD treatment combination to be taken orally daily, during or immediately after meals with dose titration at day 6 and 12 if the average fasting blood glucose (FBG) level is ≥7 mmol/L (126 mg/dL) and then dosage will be maintained for the remainder of the treatment period Participants in the intervention group initially receiving voglibose 0.2mg + metformin 500mg BD will be dose-titrated to voglibose 0.3mg +metformin 1g BD.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint.
Study: NCT05688332
Drug: Glibenclamide + Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The drugs (glibenclamide + metformin), in the control or comparator group will also be taken orally, glibenclamide once a day (OD) before meals, and metformin twice a day (BD) also before meals. These drugs will also be taken with a dose-titration at days 6 and 12 if the average is FBG level will be ≥ 7 mmol/L and the dose will be maintained for the remainder of the study period.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint. In this group, participants will initially receive glibenclamide 5mg once daily (OD) + metformin 500mg BD then will be dose-titrated to glibenclamide 10mg OD + metformin 1g BD.
Study: NCT06066008
Drug: ZM-01-H
Normalized name: ZM-39923
DrugBank: ZM-39923 (DB17064)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV-hRS1 intravitreal injection of high dose
Study: NCT04547153
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/square metre/day civ D1-D21
Study: NCT04547153
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/square metre ivdrip D1, D8, D15
Study: NCT06429475
Drug: Budesonide/formoterol
Normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The Investigational Medicinal Product (IMP) consists of a combination of Budesonide (corticosteroid) and Formoterol Furamate (fast-acting β2 agonist) dihydrate. The IMP is currently available and registered in dry powder form turbuhaler (Symbicort) and a pressurised metered dose inhaler (Vannair).~The recommended doses are pMDI/DPI 80/4.5 1-2 puffs twice daily OR 1 puff as needed (a maximum daily dose of 8 puffs) for children 6-11 years of age and 160/4.5 1-2 inhalations twice daily or 1 puff as needed (a maximum daily dose of 12 puffs) for adolescents 12-18 years.
Study: NCT06025162
Drug: enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose of enoxaparin at 48 hours post-VTE prophylaxis initiation
Study: NCT05927857
Drug: Ramucirumab /Experimental
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: infusional 8mg/kg over 60 minutes day 1, every 14 days.
Study: NCT06185361
Drug: Desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: desmopressin
Study: NCT04876677
Drug: Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two inhalations bid: 4 inhalations; total daily dose of 400/24/50 μg BDP/FF/GB
Study: NCT04984525
Drug: SYNB1934
Normalized name: SYNB1934
DrugBank: Labafenogene marselecobac (DB17618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYNB1934 is formulated as a nonsterile solution intended for oral administration
Study: NCT02197650
Drug: suspension of erythrocytes encapsulating L-asparaginase
Normalized name: Erythrocyte encapsulated l-asparaginase
DrugBank: Red blood cell-encapsulated L-asparaginase (DB17477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythrocytes encapsulating L-asparaginase
Study: NCT06044974
Drug: Epidermal Growth Factor
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidermal growth factor EGF-genesis by Dermaquel Paris n into masseter and temporalis muscles. Each muscle will be divided into 3 zones; origin, body and insertion for masseter muscle, anterior, middle, and posterior for temporalis muscle
Study: NCT05725343
Drug: Canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumabwill be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.
Study: NCT05491304
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single drug in non-severe group; combined with etoposide±ruxolitinib in severe group.
Study: NCT05491304
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Used in severe group combined with etoposide.
Study: NCT05491304
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single drug in non-severe group; combined with etoposide and dexamethasone in severe group.
Study: NCT05999968
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT05999968
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT04813523
Drug: Pembrolizumab Injection [Keytruda]
Normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant period: pembrolizumab 200mg IV, Q3W with three cycles. Adjuvant period: pembrolizumab 200 mg IV, Q3W, up to one year, which should be performed within 3-6 weeks after surgery.
Study: NCT05026203
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine hydrochloride 0.5 mg/kg intravenous administer in 40 minutes per day for 3 consecutive days
Study: NCT05026203
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam
Study: NCT05651880
Drug: Baricitinib 4 MG
Normalized name: baricitinib 4 MG
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 mg per day for 6 months (For patients with creatinine clearance between 30 and 60 mL/min at baseline or during the study, the dosage of baricitinib will be 2 mg daily)
Study: NCT06041204
Drug: Letrozole 2.5mg
Normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 2.5mg letrozole tablets orally daily for 5 days starting on day 3 of menstrual cycle. The 2.5mg dose will be maintained for at least the first 3 cycles. If no ovulation after 3 cycles, dose cautiously increased up to 7.5mg maximum. Once minimum ovulation dose determined, it will be continued for up to 6 cycles total or until pregnancy occurs. Compliance monitored by pill counts and diary. Ovulation assessed by follicular monitoring and progesterone levels. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Maximum treatment duration is 6 ovulatory cycles or 6 months. Tablets taken at same time each day.
Study: NCT04121208
Drug: JNJ-40346527
Normalized name: JNJ-40346527
DrugBank: JNJ-40346527 (DB12504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active study drug
Study: NCT05880693
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group 1 received dexmedetomidine
Study: NCT05880693
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the group 2 received magnesium sulfate
Study: NCT04076748
Drug: EMONO
Normalized name: Lemonol
DrugBank: 3'-Uridinemonophosphate (DB02714)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the control group, patients will receive EMONO then IV morphine as soon as possible.
Study: NCT04778956
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); Toripalimab should be completed for 2 cycles at 1-2 weeks before surgery, and continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
Study: NCT05292131
Drug: bimekizumab
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Study participants will receive a single dose of bimekizumab (BKZ) administered subcutaneously in the Treatment Period.